The global autoimmune disease therapeutics market is likely to be valued at US$ 71,466.47 million in 2023 and is predicted to secure a moderate-paced CAGR of 5.6% during the forecast period. The market is expected to grow at a value of US$ 123,507.30 million by 2033. A historical CAGR of 3.6% has been recorded during the analysis by Future Market Insights.
It is identified that there are more than 80 different types of autoimmune disorders amongst which multiple sclerosis, IBS, lupus, type 1 diabetes, psoriasis, rheumatoid arthritis, and others are the most common forms of autoimmune diseases.
| Attributes | Details |
|---|---|
| Historical Value (2022) | US$ 68,410.54 million |
| Current Year Value (2023) | US$ 71,466.47 million |
| Expected Forecast Value (2033) | US$ 123,507.30 million |
| Historical CAGR (2018 to 2022) | 3.6% |
| Projected CAGR (2023 to 2033) | 5.6% |
The adoption of autoimmune disease therapeutics insights reveals they are being used as these diseases cause abnormally low activity or overactivity of the immune systems, attacking the body’s own tissues and cells, which need to be treated therapeutically.
It is witnessed that autoimmune diseases decrease the body’s ability to fight foreign agents, and it is more common in women than in men. Therefore, it is anticipated that the autoimmune disease therapeutics market is likely to have significant growth during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market for autoimmune disease therapeutics is expected to have increased growth in the coming years and there are many factors identified that are likely to bolster the market dynamics in a positive direction.
Besides the propelling factors, a number of challenges are also identified. Let us take an in-depth look at the following drivers and restraints.
DRIVERS:
RESTRAINTS:
North America is projected to dominate the global autoimmune disease therapeutics market during the forecast period. Currently, the region is accountable for 38.3% of the total market share of autoimmune disease therapeutics.
The growth in the North American region can be attributed to:
Europe is projected to have slow-paced growth during the forecast period, yet it will hold a significant share of the market. At present, the European region is accountable for 27.3% of the total market share of autoimmune disease therapeutics.
The growth can be attributed to:
Principal Consultant
| Countries | 2022 Value Share in Global Market |
|---|---|
| United States | 33.8% |
| Germany | 5.4% |
| Japan | 4.1% |
The United States has witnessed a significant increase in the prevalence of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and Crohn's disease. While autoimmune diseases are generally uncommon, the National Institutes for Health (NIH) approximates that they have an impact on about 5% to 8% of the population in the United States.
A GlobalData epidemiology analysis focusing on two prevalent autoimmune diseases, namely systemic lupus erythematosus and Sjögren's syndrome, revealed that the United States and the United Kingdom have higher rates of occurrence compared to other nations. This rising prevalence is driving the demand for autoimmune disease therapeutics.
The United States has a significantly high healthcare expenditure rate compared to other countries worldwide. This substantial investment in healthcare infrastructure provides a conducive environment for market growth. The United States maintains a robust regulatory framework for drug approvals and safety monitoring. The United States Food and Drug Administration (FDA) plays a pivotal role in ensuring the quality, safety, and efficacy of autoimmune disease therapeutics, thereby instilling confidence among healthcare professionals and patients.
The Germany autoimmune disease therapeutics market is experiencing significant growth due to the rising prevalence of autoimmune diseases, advancements in medical technology, and increasing healthcare expenditure. The Multiple Sclerosis Trust reported a global estimate of 2.5 million individuals living with multiple sclerosis in 2020, with Germany having the highest prevalence.
Germany is renowned for its advanced healthcare infrastructure and technological innovations. The country has been at the forefront of developing novel autoimmune disease therapeutics, including targeted biologics and personalized medicine approaches. The integration of technology, such as artificial intelligence and genomic profiling, is enhancing treatment outcomes and propelling market growth.
The increasing collaboration among industry participants in the country has led to the development of numerous products, driving the expansion of the market. In June 2022, Theradiag joined forces with Quotient Ltd, a diagnostics company in the commercial stage, to leverage Quotient's MosaiQ technology and create an advanced autoimmune diagnostics solution.
Japan has experienced a rise in the prevalence of autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and inflammatory bowel disease. This trend can be attributed to factors such as an aging population, environmental factors, and changing lifestyles.
Japan has a well-developed healthcare system, and its population enjoys high awareness and access to healthcare services. This facilitates early diagnosis and treatment of autoimmune diseases, leading to better patient outcomes. Additionally, the Japanese government provides comprehensive healthcare coverage, ensuring the affordability of autoimmune disease therapeutics.
The Japanese government has actively promoted research and development in autoimmune disease therapeutics. Funding support, regulatory incentives, and streamlined approval processes have encouraged pharmaceutical companies to invest in innovative treatments, leading to a robust pipeline of drugs in development.
| Countries | Value CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 3.9% |
| China | 6.8% |
| India | 5.6% |
The United Kingdom has observed a rise in the prevalence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. According to a recent study, it has been discovered that autoimmune disorders, including type 1 diabetes and rheumatoid arthritis, affect around 10% of the population in the United Kingdom. Factors such as genetic predisposition, environmental factors, and lifestyle changes contribute to the growing burden of autoimmune diseases, thereby driving the demand for therapeutics.
Personalized medicine has gained traction in the United Kingdom, with a focus on tailoring treatment strategies based on individual patient characteristics. The integration of biomarker analysis, genetic testing, and patient profiling enables physicians to optimize therapeutic interventions, leading to better patient outcomes. The United Kingdom government has also implemented initiatives to address autoimmune diseases' burden and improve patient care.
The China autoimmune disease therapeutics market has witnessed significant growth over the past few years. In China, the prevalence of autoimmune diseases has been on the rise due to factors such as changing lifestyles, environmental factors, and genetic predisposition. This has created a substantial market for autoimmune disease therapeutics in the country.
There is a shift toward the adoption of biologic therapies for autoimmune diseases in China. Biologics offer targeted treatment options with improved efficacy and reduced side effects compared to conventional therapies. The demand for biologics is expected to increase further in the coming years.
Chinese traditional medicine practices, such as acupuncture and herbal remedies, are being integrated with conventional therapies for autoimmune diseases. This integration provides holistic treatment options and is favored by a significant portion of the population in China.
The rapid growth of digital healthcare in China presents opportunities for autoimmune disease therapeutics. Telemedicine, remote monitoring, and digital health platforms provide innovative ways to improve patient outcomes and enhance access to care.
India has witnessed a surge in the prevalence of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and psoriasis, among others. In contemporary times, autoimmune diseases, which were previously deemed uncommon, have emerged as one of the leading contributors to chronic illnesses in India. The growing incidence of these diseases can be attributed to various factors such as genetic predisposition, environmental triggers, and lifestyle changes. This trend has created a significant demand for autoimmune disease therapeutics in the country.
The Indian government has taken several initiatives to improve healthcare access and affordability in the country. Initiatives such as the National Health Policy and Ayushman Bharat have the potential to impact the India autoimmune disease therapeutics market positively. These programs aim to provide universal health coverage and improve access to essential medicines, including those for autoimmune diseases
| Segment | 2022 Value Share in Global Market |
|---|---|
| Anti-inflammatory Drug Class Type | 43.1% |
| Hospital Pharmacy Sales Channel | 77.2% |
The dominance of the anti-inflammatory drug class in the autoimmune disease therapeutics market can be attributed to various factors:
Hospital pharmacies are likely to play a significant role in the distribution of autoimmune disease therapeutics for several reasons:
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The start-up companies in the autoimmune disease therapeutics market are intensifying their focus on frequent innovations and indulging themselves in mergers and acquisitions to develop effective therapeutic solutions for the end-users.
Three Start-ups Gaining Traction in The Market
Viela Bio - The USA-based start-up creates a novel therapeutic to treat neuromyelitis optica spectrum disorder, a neuroinflammatory disorder that causes irreversible blindness and paralysis. UPLIZNA targets the aquaporin-4 antibody in adult patients. A combination of immunosuppressive therapies with UPLIZNA helps patients overcome this rare disease with minimal side effects, including urinary tract infections and influenza.
Immundnz - This British start-up develops COMPIT, an in vitro immune response platform to understand responses in autoimmune disorders. The platform is versatile and helps analyze various parameters including cell viability and cytotoxicity. COMPIT consists of a variety of immune and protein assays that are customizable according to any experimental model to study drug immunology or immune safety.
Landos Biopharma - The Swedish start-up is working on novel therapeutic drugs to treat gastrointestinal immune disorders. The start-up’s lead candidate BT-11, an oral therapeutic drug for treating ulcerative colitis, is currently undergoing Phase II clinical trials. BT-11 activates the lanthionine synthetase C-like protein 2 (LANCL2) pathway, which plays a pivotal role in metabolism and immune response.
Key Market Players Revolutionizing the Autoimmune Disease Therapeutics Market
The market players are focusing on organic growth strategies such as product launches, product approvals, and other such patents and events. They are anticipated to have lucrative growth opportunities in the future with rising demand for autoimmune disease drugs in the global market.
Recent Developments
The projected revenue of the market by 2033 is US$ 123,507.30 million.
The market CAGR for 2033 is projected to be 3.6%.
The market is valued at US$ 71,466.47 million in 2023.
North America holds a substantial market share.
Increasing prevalence of autoimmune diseases in North America is key driving factor.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class Type 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class Type, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class Type, 2023 to 2033 5.3.1. Anti-inflammatory 5.3.2. Antihyperglycemics 5.3.3. NSAIDs 5.3.4. Interferons 5.3.5. Others 5.4. Y-o-Y Growth Trend Analysis By Drug Class Type, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class Type, 2023 to 2033 6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Indication 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Indication, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 6.3.1. Rheumatic Disease 6.3.2. Type 1 Diabetes 6.3.3. Multiple Sclerosis 6.3.4. Inflammatory Bowel Disease 6.3.5. Other Indications 6.4. Y-o-Y Growth Trend Analysis By Indication, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Indication, 2023 to 2033 7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sales Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Sales Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Sales Channel , 2023 to 2033 7.3.1. Hospital Pharmacy 7.3.2. Drug Store & Retail Pharmacy 7.3.3. Online Store 7.4. Y-o-Y Growth Trend Analysis By Sales Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Sales Channel , 2023 to 2033 8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Western Europe 8.3.4. Eastern Europe 8.3.5. South Asia and Pacific 8.3.6. East Asia 8.3.7. Middle East and Africa 8.4. Market Attractiveness Analysis By Region 9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. U.S. 9.2.1.2. Canada 9.2.2. By Drug Class Type 9.2.3. By Indication 9.2.4. By Sales Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class Type 9.3.3. By Indication 9.3.4. By Sales Channel 9.4. Key Takeaways 10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class Type 10.2.3. By Indication 10.2.4. By Sales Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class Type 10.3.3. By Indication 10.3.4. By Sales Channel 10.4. Key Takeaways 11. Western Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. U.K. 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Western Europe 11.2.2. By Drug Class Type 11.2.3. By Indication 11.2.4. By Sales Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class Type 11.3.3. By Indication 11.3.4. By Sales Channel 11.4. Key Takeaways 12. Eastern Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. Poland 12.2.1.2. Russia 12.2.1.3. Czech Republic 12.2.1.4. Romania 12.2.1.5. Rest of Eastern Europe 12.2.2. By Drug Class Type 12.2.3. By Indication 12.2.4. By Sales Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class Type 12.3.3. By Indication 12.3.4. By Sales Channel 12.4. Key Takeaways 13. South Asia and Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. India 13.2.1.2. Bangladesh 13.2.1.3. Australia 13.2.1.4. New Zealand 13.2.1.5. Rest of South Asia and Pacific 13.2.2. By Drug Class Type 13.2.3. By Indication 13.2.4. By Sales Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class Type 13.3.3. By Indication 13.3.4. By Sales Channel 13.4. Key Takeaways 14. East Asia Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. China 14.2.1.2. Japan 14.2.1.3. South Korea 14.2.2. By Drug Class Type 14.2.3. By Indication 14.2.4. By Sales Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class Type 14.3.3. By Indication 14.3.4. By Sales Channel 14.4. Key Takeaways 15. Middle East and Africa Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class Type 15.2.3. By Indication 15.2.4. By Sales Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class Type 15.3.3. By Indication 15.3.4. By Sales Channel 15.4. Key Takeaways 16. Key Countries Analysis 16.1. U.S. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class Type 16.1.2.2. By Indication 16.1.2.3. By Sales Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class Type 16.2.2.2. By Indication 16.2.2.3. By Sales Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class Type 16.3.2.2. By Indication 16.3.2.3. By Sales Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class Type 16.4.2.2. By Indication 16.4.2.3. By Sales Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class Type 16.5.2.2. By Indication 16.5.2.3. By Sales Channel 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class Type 16.6.2.2. By Indication 16.6.2.3. By Sales Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class Type 16.7.2.2. By Indication 16.7.2.3. By Sales Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class Type 16.8.2.2. By Indication 16.8.2.3. By Sales Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class Type 16.9.2.2. By Indication 16.9.2.3. By Sales Channel 16.10. Poland 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class Type 16.10.2.2. By Indication 16.10.2.3. By Sales Channel 16.11. Russia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class Type 16.11.2.2. By Indication 16.11.2.3. By Sales Channel 16.12. Czech Republic 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class Type 16.12.2.2. By Indication 16.12.2.3. By Sales Channel 16.13. Romania 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class Type 16.13.2.2. By Indication 16.13.2.3. By Sales Channel 16.14. India 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class Type 16.14.2.2. By Indication 16.14.2.3. By Sales Channel 16.15. Bangladesh 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class Type 16.15.2.2. By Indication 16.15.2.3. By Sales Channel 16.16. Australia 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class Type 16.16.2.2. By Indication 16.16.2.3. By Sales Channel 16.17. New Zealand 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class Type 16.17.2.2. By Indication 16.17.2.3. By Sales Channel 16.18. China 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class Type 16.18.2.2. By Indication 16.18.2.3. By Sales Channel 16.19. Japan 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class Type 16.19.2.2. By Indication 16.19.2.3. By Sales Channel 16.20. South Korea 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class Type 16.20.2.2. By Indication 16.20.2.3. By Sales Channel 16.21. GCC Countries 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class Type 16.21.2.2. By Indication 16.21.2.3. By Sales Channel 16.22. South Africa 16.22.1. Pricing Analysis 16.22.2. Market Share Analysis, 2022 16.22.2.1. By Drug Class Type 16.22.2.2. By Indication 16.22.2.3. By Sales Channel 16.23. Israel 16.23.1. Pricing Analysis 16.23.2. Market Share Analysis, 2022 16.23.2.1. By Drug Class Type 16.23.2.2. By Indication 16.23.2.3. By Sales Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class Type 17.3.3. By Indication 17.3.4. By Sales Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Abbott Laboratories 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. AbbVie Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. Amgen Inc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. AstraZeneca Plc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Bristol-Myers Squibb Company 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. F. Hoffmann-La Roche Ltd. (Genentech, Inc.,) 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Johnson & Johnson 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Novartis AG 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Pfizer Inc. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. UCB S.A. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Autoimmune Disease Therapeutics Market
